Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN11 | Q06124 | 13/20 | 1.00 |
| ▸ | NR0B2 | Q15466 | 4/20 | 1.00 |
| ▸ | RARB | P10826 | 3/20 | 0.74 |
| ▸ | PTPRCAP | Q14761 | 2/20 | 0.63 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.59 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.59 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.59 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.59 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.59 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.59 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.59 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.59 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.59 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.58 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.58 |
| ▸ | RARA | P10276 | 1/20 | 0.55 |
| ▸ | RARG | P13631 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29604865 | 1.00 | PTPN11 (1.00) | PTPN11NR0B2RARBPTPRCAPHDAC4 | |
| SCHEMBL1914215 | 1.00 | PTPN11 (1.00) | PTPN11NR0B2RARBPTPRCAPHDAC4 | |
| SCHEMBL12257833 | 0.91 | PTPN11 (0.83) | PTPN11NR0B2RARBPTPRCAPHDAC4 | |
| SCHEMBL2389152 | 0.89 | RARB (0.80) | PTPN11NR0B2RARBPTPRCAPHDAC4 | |
| SCHEMBL2389155 | 0.89 | RARB (0.80) | PTPN11NR0B2RARBPTPRCAPHDAC4 | |
| SCHEMBL3289761 | 0.89 | PTPN11 (0.80) | PTPN11NR0B2RARBPTPRCAPHDAC4 | |
| SCHEMBL3289754 | 0.89 | PTPN11 (0.80) | PTPN11NR0B2RARBPTPRCAPHDAC4 | |
| SCHEMBL2391213 | 0.87 | PTPN11 (0.77) | PTPN11NR0B2RARBPTPRCAPHDAC4 | |
| SCHEMBL2391204 | 0.87 | PTPN11 (0.77) | PTPN11NR0B2RARBPTPRCAPHDAC4 | |
| SCHEMBL2407028 | 0.87 | PTPN11 (0.77) | PTPN11NR0B2RARBPTPRCAPHDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020198576-A1 | METHODS OF MODULATING REGULATORY T CELLS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2020-10-01 | — | — | WO | disclosed |
| WO-2020130863-A1 | METHODS OF TREATMENT OF CANCER ASSOCIATED WITH CENTROSOME AMPLIFICATION | INSTITUTO DE MEDICINA MOLECULAR (PT) | 2020-06-25 | — | — | WO | disclosed |
| US-9096544-B2 | Therapeutic compounds | WAYNE STATE UNIVERSITY (US) | 2015-08-04 | — | — | US | disclosed |
| US-9096544-B2 | Therapeutic compounds | WAYNE STATE UNIVERSITY (US) | 2015-08-04 | — | — | US | disclosed |
| US-9096544-B2 | Therapeutic compounds | WAYNE STATE UNIVERSITY (US) | 2015-08-04 | — | — | US | disclosed |
| EP-2367781-B1 | RETINOID DERIVATIVES ENDOWED WITH CYTOTOXIC AND/OR ANTIANGIOGENIC PROPERTIES | SIGMA TAU IND FARMACEUTI (IT) | 2013-10-02 | — | — | EP | disclosed |
| US-8530517-B2 | Retinoid derivatives endowed with cytotoxic and/or antiangiogenic properties | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2013-09-10 | — | — | US | disclosed |
| US-20130137699-A1 | THERAPEUTIC COMPOUNDS | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2013-05-30 | — | — | US | disclosed |
| US-20130137699-A1 | THERAPEUTIC COMPOUNDS | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2013-05-30 | — | — | US | disclosed |
| US-20130137699-A1 | THERAPEUTIC COMPOUNDS | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2013-05-30 | — | — | US | disclosed |
| WO-2008033466-A2 | COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES | COMBINATORX (SINGAPORE) PRE. LTD. (SG) | 2008-03-20 | — | — | WO | disclosed |
| EP-1896399-A1 | BIPHENYL AND NAPHTHYL-PHENYL HYDROXAMIC ACID DERIVATIVES | SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. (IT) | 2008-03-12 | — | — | EP | disclosed |
| CN-100348569-C | Induction of apoptosis in cancer cells | BURNHAM INST (US) | 2007-11-14 | — | — | CN | disclosed |
| WO-2007000383-A1 | BIPHENYL AND NAPHTHYL-PHENYL HYDROXAMIC ACID DERIVATIVES | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2007-01-04 | — | — | WO | disclosed |
| WO-2007000383-A1 | BIPHENYL AND NAPHTHYL-PHENYL HYDROXAMIC ACID DERIVATIVES | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2007-01-04 | — | — | WO | disclosed |
| US-7053071-B2 | For therapy of leukemia or other forms of cancer or for treating disease conditions caused by apoptosis of cells | THE BURNHAM INSTITUTE (US) | 2006-05-30 | — | — | US | disclosed |
| CN-1659130-A | Induction of apoptosis in cancer cells | BURNHAM INST (US) | 2005-08-24 | — | — | CN | disclosed |
| EP-1456165-A1 | INDUCTION OF APOPTOSIS IN CANCER CELLS | The Burnham Institute (US) | 2004-09-15 | — | — | EP | disclosed |
| US-20030176506-A1 | Induction of apoptosis in cancer cells | BURNHAM INSTITUTE FOR MEDICAL RESEARCH | 2003-09-18 | — | — | US | disclosed |
| WO-2003048101-A1 | INDUCTION OF APOPTOSIS IN CANCER CELLS | THE BURNHAM INSTITUTE (US) | 2003-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130137699-A1 | THERAPEUTIC COMPOUNDS | BAX, MCL1, TMBIM6 | PTPN11 2827/4885NR0B2 3403/4885RARB 3599/4885 |
| US-20030176506-A1 | Induction of apoptosis in cancer cells | MCL1, BAD, BCL2 | PTPN11 2842/4885NR0B2 2377/4885RARB 577/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.